Abstract Library

#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study

Introduction: CS associated with NETs can have a negative impact on patients’ QoL.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G,

Keywords: quality of life,

#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)

Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G,

Keywords: PRO,

#550 Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy

Introduction: Y90-DOTATATE and Y90-DOTATOC are established treatments for patients with advanced neuroendocrine tumours. Outcomes associated with improved survival following therapy are still unclear.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Gilbert T, Mckane G, Banks M, Poston G, Vora J,

Keywords: Y90 DOTATOC/DOTATATE, survival,

#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease

Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Ardill J, Poston G,

Keywords: carcinoid disease, chromogranin A, Neurokinin A, N-Terminal Barin Naturetic Peptide, carcinoid heart disease, echocardiography,

#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease

Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Poston G, Cuthbertson D,

Keywords: carcinoid heart disease, tissue doppler imaging, carcinoid syndrome, metastatic carcinoid disease, echocardiography,